Cardiol Therapeutics (CRDL) 6-K: U.S. patent allowance to 2040

Cardiol Therapeutics (CRDL) furnished a Form 6-K that includes a news release stating it received a U.S. patent allowance broadly protecting its heart drugs to late 2040.

Accepted by SEC EDGAR 11/13/2025 - 07:57 AM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Cardiol Therapeutics (CRDL) furnished a Form 6-K that includes a news release stating it received a U.S. patent allowance broadly protecting its heart drugs to late 2040. The exhibit is a news release dated November 13, 2025.

The company indicates it files annual reports under cover of Form 40-F as a foreign private issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cardiol Therapeutics (CRDL) report in this Form 6-K?

It furnished a news release stating it received a U.S. patent allowance broadly protecting its heart drugs to late 2040.

What exhibit was included in CRDL’s 6-K?

Exhibit 99.1, a News Release dated November 13, 2025.

What is the key timeline mentioned for CRDL’s patent allowance?

Protection is described as extending to late 2040.

Does Cardiol Therapeutics file annual reports on Form 20-F or 40-F?

It indicates filing annual reports under cover Form 40-F.

What is the subject of the Exhibit 99.1 news release for CRDL?

“Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040.”

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[ ] Form 20-F [X] Form 40-F

SUBMITTED HEREWITH

Exhibits

Exhibit		Description

99.1		News Release dated November 13, 2025 - Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOL THERAPEUTICS INC.
	(Registrant)

Date: November 13, 2025	By:	/s/ Chris Waddick

		Chris Waddick
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR